SCHEMBL867322

SCHEMBL867322

CC(=O)N(C)CC=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2273019 0.78
SCHEMBL1446017 0.78
SCHEMBL207433 0.76
SCHEMBL14029230 0.76
SCHEMBL20221160 0.76
SCHEMBL19965813 0.76
SCHEMBL12049258 0.74
SCHEMBL27504265 0.74 PHF8 (0.30)
SCHEMBL4195366 0.74 PHF8 (0.33)
SCHEMBL25762055 0.72 CHRNB2 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 US claimed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 EP claimed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 WO claimed
US-11602527-B2 Methods of use of cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2023-03-14 US disclosed
US-20210275508-A1 METHODS OF USE OF CYCLOPAMINE ANALOGS INFINITY PHARMACEUTICALS, INC. 2021-09-09 US disclosed
US-11007181-B2 Cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2021-05-18 US disclosed
US-10821102-B2 Methods of use of cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2020-11-03 US disclosed
US-20200121658-A1 CYCLOPAMINE ANALOGS ROYALTY SECURITY, LLC 2020-04-23 US disclosed
US-10406139-B2 Cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2019-09-10 US disclosed
EP-2767577-B1 Additive compositions with a friction modifier and a dispersant AFTON CHEMICAL CORP (US) 2019-08-28 EP disclosed
US-10314827-B2 Methods of use of cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2019-06-11 US disclosed
US-4256746-A ANTITUMOR AGENTS; MICROBIOCIDES; MITOSIS TAKEDA CHEMICAL INDUSTRIES (JP) 1981-03-17 US disclosed
EP-0014402-A1 Novel 20-0-acylmaytansinoids, process for their preparation and pharmaceutical compositions containing them Takeda Chemical Industries, Ltd. (JP) 1980-08-20 EP disclosed
EP-0011277-A1 Dechloromaytansinoids, their production and use and pharmaceutical compositions containing them Takeda Chemical Industries, Ltd. (JP) 1980-05-28 EP disclosed
EP-0011276-A1 Maytansinoids, their production and use Takeda Chemical Industries, Ltd. (JP) 1980-05-28 EP disclosed
EP-0004466-A1 Demethyl maytansinoids and methods for producing them Takeda Chemical Industries, Ltd. (JP) 1979-10-03 EP disclosed
US-4044123-A ANTIBIOTICS SCHERING CORPORATION (US) 1977-08-23 US disclosed
US-4002608-A ANTIBACTERIALS SCHERING CORPORATION (US) 1977-01-11 US disclosed
US-4002742-A 1-N-alkyl-4,6-di-(aminoglycosyl)-1,3-diaminocyclitols, methods for their manufacture, methods for their use as antibacterial agents, and compositions useful therefor SCHERING CORPORATION (US) 1977-01-11 US disclosed